Blood Brain Barrier Technologies Global Market Report 2024

The blood brain barrier technologies market size has grown exponentially in recent years. It will grow from $1.23 billion in 2023 to $1.57 billion in 2024 at a compound annual growth rate (CAGR) of 27.8%. The growth seen in the historic period can be linked to several factors, including a focus on patient-centric drug development, augmented funding for research initiatives, heightened disease awareness, a rise in the prevalence of neurological disorders, and advancements in drug innovation and delivery devices.

The blood brain barrier technologies market size is expected to see exponential growth in the next few years. It will grow to $4.2 billion in 2028 at a compound annual growth rate (CAGR) of 27.9%. The projected growth in the forecast period can be attributed to several factors, including a heightened focus on orphan drugs and rare neurological disorders, the escalating burden associated with central nervous system (CNS) conditions, a rise in neurological disease incidence coupled with an aging population, advancements in biomarker discovery, and a robust healthcare infrastructure. Major trends expected in this period encompass progress in nanotechnology, increased research funding, expansion in treatments for CNS disorders, growing demand for non-invasive delivery methods, development of innovative drug delivery systems, collaboration between pharmaceutical and biotech firms, and enhanced regulatory backing.

The blood-brain barrier technologies market is poised for growth due to the increasing prevalence of neurological diseases. These diseases affect both the central and peripheral nervous systems, including various components such as the brain, spinal cord, nerves, and muscles. Factors contributing to the rising incidence of neurological diseases include an aging population, improved diagnostic methods, and lifestyle changes leading to higher-risk factors such as obesity and sedentary lifestyles. Blood-brain barrier technology plays a crucial role in improving drug delivery to the brain, addressing a major challenge in treating neurological disorders and significantly impacting the management of these diseases. For example, the Parkinson’s Foundation reported a steep 50% increase in diagnosed cases of Parkinson's disease in the U.S., reaching 90,000 people in December 2022, compared to 2021. This trend underscores the driving force behind the growth of the blood-brain barrier technologies market.

Leading companies in this market are concentrating on developing innovative, patented technologies to enhance drug delivery specifically to the brain. These advancements represent significant progress in overcoming the hurdles associated with delivering therapeutics to the brain, offering promising solutions for unmet medical needs in neurology. For instance, BioArctic AB was granted a new patent by the US Patent and Trademark Office (USPTO) in November 2022 for technology that enhances the transport of biopharmaceuticals across the blood-brain barrier, part of their Brain Transporter patent portfolio aimed at improving drug effectiveness by bypassing the brain's natural protective barrier.

In January 2021, Eli Lilly and Company, a US healthcare firm, acquired Prevail Therapeutics Inc. Although the acquisition amount was not disclosed. The purpose of this acquisition is to strengthen Lilly's abilities in developing and marketing drugs for neuroscience, particularly by establishing a gene therapy program focused on delivering innovative treatments for individuals with neurodegenerative disorders. Prevail Therapeutics Inc., an American biotechnology company specializing in blood-brain barrier (BBB) technologies, was the target of this acquisition.

Major companies operating in the blood brain barrier technologies market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol Myers Squibb, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Bayer AG, Biogen Inc., Eisai Co. Ltd., Alnylam Pharmaceuticals Inc., JCR Pharma Co. Ltd., Genentech Inc., Denali Therapeutics Inc., Voyager Therapeutics Inc., Fujifilm Cellular Dynamics Inc., Angiochem Inc., Ossianix Inc., ArmaGen Inc., BiOasis Technologies Inc., BioArctic AB.

North America was the largest region in the blood brain barrier technologies market in 2023. The regions covered in the blood brain barrier technologies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the blood brain barrier technologies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Blood-brain barrier (BBB) technologies encompass advanced methods and innovations crafted to explore, manipulate, and traverse the blood-brain barrier. These technologies are geared towards delivering therapeutic agents to the brain while safeguarding the barrier's protective functions, thus aiding in the treatment of neurological disorders.

Key BBB technologies include the bispecific antibody receptor-mediated transcytosis (RMT) approach, the trojan horse approach, methods to increase permeability, passive diffusion, and others. The bispecific antibody receptor-mediated transcytosis (RMT) approach entails utilizing bispecific antibodies capable of binding to targets within the brain and specific receptors on the blood-brain barrier, facilitating their transport into the brain. These technologies find applications in treating conditions such as Alzheimer's disease, epilepsy, Parkinson's disease, multiple sclerosis, Hunter's syndrome, brain cancer, and more. End-users include hospitals, surgical centers, research institutes, and others.

The blood-brain barrier technologies market research report is one of a series of new reports that provides blood-brain barrier technologies market statistics, including blood-brain barrier technologies industry global market size, regional shares, competitors with a blood-brain barrier technologies market share, detailed blood-brain barrier technologies market segments, market trends and opportunities, and any further data you may need to thrive in the blood-brain barrier technologies industry. This blood-brain barrier technologies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The blood brain barrier technologies market consists of revenues earned by entities by providing services such as drug delivery systems and permeability testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The blood brain barrier technologies market also includes sales of microfluidic devices, biomarkers, chemical permeabilizers, and receptor-mediated transport enhancers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.